(NASDAQ: FHTX) Foghorn Therapeutics's forecast annual revenue growth rate of -0.08% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Foghorn Therapeutics's revenue in 2026 is $36,739,000.On average, 12 Wall Street analysts forecast FHTX's revenue for 2026 to be $2,054,613,128, with the lowest FHTX revenue forecast at $1,125,470,490, and the highest FHTX revenue forecast at $2,762,307,927. On average, 12 Wall Street analysts forecast FHTX's revenue for 2027 to be $2,205,451,828, with the lowest FHTX revenue forecast at $1,163,952,174, and the highest FHTX revenue forecast at $3,117,729,038.
In 2028, FHTX is forecast to generate $2,133,239,285 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $5,115,747,961.